These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 977795)
61. Biological availability of digoxin from Lanoxin produced in the United Kingdom. Johnson BF; Fowle AS; Lader S; Fox J; Munro-Faure AD Br Med J; 1973 Nov; 4(5888):323-6. PubMed ID: 4758424 [TBL] [Abstract][Full Text] [Related]
62. Clinical problems associated with the variable biologic availability of digoxin. Shaw TR Am Heart J; 1974 Mar; 87(3):399-401. PubMed ID: 4812378 [No Abstract] [Full Text] [Related]
63. Trade names or approved names. Part III. Special cases. Clinical trials. Garnham JC Postgrad Med J; 1974 Feb; 50(580):114-20. PubMed ID: 4465771 [TBL] [Abstract][Full Text] [Related]
64. [Evaluation of the physiological availability of drug substances in capsules]. Mikhaĭlova GS Farmatsiia; 1975; 24(1):78-82. PubMed ID: 770209 [No Abstract] [Full Text] [Related]
66. [Bioavailability, proof of efficacy and their consequences for drug legislation (author's transl)]. Schnieders B Arzneimittelforschung; 1976; 26(1A):158-63. PubMed ID: 947195 [TBL] [Abstract][Full Text] [Related]
68. An overview of the analysis and interpretation of bioavailability studies in man. Wagner JG Pharmacology; 1972; 8(1):102-17. PubMed ID: 4644642 [No Abstract] [Full Text] [Related]
69. Proceedings: Bio availability of digoxin and derivatives. Rietbrock N; Guggenmos J Naunyn Schmiedebergs Arch Pharmacol; 1974; 282(Suppl):suppl 282:R80. PubMed ID: 4276634 [No Abstract] [Full Text] [Related]
70. [The biological availability of several digoxin preparations used in the Netherlands]. Dunning AJ; Buurke EJ; Roos JC; Paalman AC; van Rooy HH Ned Tijdschr Geneeskd; 1973 Dec; 117(48):1809-16. PubMed ID: 4788673 [No Abstract] [Full Text] [Related]
71. [Biopharmaceutical classification system--experimental model of the prediction of drug bioavailability]. Golovenko NIa; Borisiuk IIu Biomed Khim; 2008; 54(4):392-407. PubMed ID: 18988456 [TBL] [Abstract][Full Text] [Related]
73. Trade names or approved names. Point II. Points of view. The clinical pharmacologist. Turner P Postgrad Med J; 1974 Feb; 50(580):93-5. PubMed ID: 4465784 [TBL] [Abstract][Full Text] [Related]
75. Drug bioequivalence. Recommendations from the Drug Bioequivalence Study Panel to the Office of Technology Assessment, Congress of the United States. J Pharmacokinet Biopharm; 1974 Oct; 2(5):433-66. PubMed ID: 4452945 [No Abstract] [Full Text] [Related]
76. [Equivalency of drugs and the problem of biological availability]. Hirtz J Rev Prat; 1973 Nov; 23(53):7-10. PubMed ID: 4802222 [No Abstract] [Full Text] [Related]
78. Doctors are pivotal to prescription struggle. Chapman S Leg Aspects Med Pract; 1979 Mar; 7(3):42-4. PubMed ID: 423688 [No Abstract] [Full Text] [Related]